Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda.

Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda.

Publication date: Mar 04, 2025

Infants born to mothers with active tuberculosis disease (ATB) are at risk of poor clinical outcomes such as low birth weight and perinatal mortality. However, little is known about the influence of maternal ATB exposure on their vaccine responses during infancy. The study explored how maternal ATB affects infants’ vaccine responses, hypothesising reduced responses to Bacille Calmette-GucE9rin (BCG) and other infant vaccines. This was a case-control study with a longitudinal component of infants born to mothers with bacteriologically confirmed ATB (cases) and infants born to mothers without ATB (controls) carried out between September 2021 and June 2022. Quantitative BCG, diphtheria, tetanus, and measles-specific IgG ELISA assays were performed on infant plasma harvested from lithium-heparin blood collected on first encounter after birth (0), at 3, 6, and 9 months. We used prism v10. 1.2, mixed-effects modelling, and Tukey’s multiple comparison testing to determine mean differences (MD) between the cases and controls at all time points. Exposed infant cases had reduced IgG titres to BCG at baseline compared to the controls (p = 0. 032), with a mean of 125. 8 vs. 141. 1 IU/mL, respectively. This difference was, however, not sustained at the other time points. Similarly, we demonstrated trends towards reduced responses to tetanus, diphtheria, and measles vaccines among infant cases at baseline and three months. However, the trend was not sustained at months six and nine. The mean titres for tetanus at baseline and 3 months for cases versus controls are 1. 744 vs. 2. 917 IU/mL (p 

Open Access PDF

Concepts Keywords
June Active tuberculosis
Lithium Infants
Mothers Mothers
Tuberculosis Vaccine response
Uganda

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH low birth weight
drug DRUGBANK BCG vaccine
disease MESH diphtheria
disease MESH tetanus
disease MESH measles
pathway KEGG Measles
drug DRUGBANK Heparin
disease IDO blood
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease IDO cell
disease IDO immune response
disease IDO susceptibility
disease MESH Mother to child transmission
disease MESH preterm birth
disease MESH perinatal death
disease MESH anomalies
disease MESH latent infection
drug DRUGBANK p-Phenylenediamine
disease MESH latent tuberculosis infection
disease MESH pertussis
pathway KEGG Pertussis
disease MESH hepatitis B
pathway KEGG Hepatitis B
drug DRUGBANK Cysteamine
drug DRUGBANK Tretamine
disease MESH anemia
drug DRUGBANK Triethylenetetramine
drug DRUGBANK L-Valine
drug DRUGBANK Podofilox
drug DRUGBANK Clostridium tetani toxoid antigen (formaldehyde inactivated)
disease MESH infections
disease MESH infant deaths
disease MESH vaccine preventable diseases
disease MESH fatal outcomes
pathway REACTOME Immune System
disease MESH preterm infants
drug DRUGBANK Indoleacetic acid
disease IDO assay
disease IDO immunodeficiency
disease IDO facility
disease MESH Infectious Diseases
disease MESH Immune reconstitution syndrome
disease IDO infection
pathway REACTOME Fertilization
disease IDO host
disease MESH Autism
disease MESH pulmonary tuberculosis
disease MESH iron deficiency anemia
disease MESH pregnancy outcome
disease IDO intervention
drug DRUGBANK Iron

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *